RAF kinase modulator compounds and methods of use thereof

US9320739B2 · kind B2 · utility

Assignee

• AMBIT BIOSCIENCES CORP. · US

Inventors

• Sunny Abraham · San Diego, US
• Shripad S. Bhagwat · San Diego, US
• Brian T. Campbell · Souderton, US
• Qi Chao · San Diego, US
• Raffaella Faraoni · San Diego, US
• Mark W. Holladay · San Diego, US
• Andiliy G. Lai · San Diego, US
• Martin Rowbottom · San Diego, US
• Eduardo Setti · San Diego, US
• Kelly G. Sprankle · Vista, US

Key dates

• Filing date: Jan 26, 2015
• Grant date: Apr 26, 2016
• Expiry date: Jan 26, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions of 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1, -trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.